Connor Clark & Lunn Investment Management Ltd. Invests $1.98 Million in The Cooper Companies, Inc. (NASDAQ:COO)

Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of The Cooper Companies, Inc. (NASDAQ:COO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 21,586 shares of the medical device company’s stock, valued at approximately $1,984,000.

A number of other institutional investors have also modified their holdings of COO. Byrne Asset Management LLC purchased a new position in shares of Cooper Companies during the fourth quarter worth approximately $33,000. OFI Invest Asset Management bought a new position in shares of Cooper Companies during the fourth quarter valued at approximately $34,000. Brown Brothers Harriman & Co. boosted its stake in shares of Cooper Companies by 191.0% during the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 275 shares in the last quarter. West Financial Advisors LLC bought a new position in shares of Cooper Companies during the fourth quarter valued at approximately $49,000. Finally, UMB Bank n.a. boosted its stake in shares of Cooper Companies by 22.5% during the fourth quarter. UMB Bank n.a. now owns 773 shares of the medical device company’s stock valued at $71,000 after purchasing an additional 142 shares in the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Price Performance

Shares of COO opened at $80.04 on Wednesday. The company has a market cap of $16.01 billion, a price-to-earnings ratio of 41.05, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The Cooper Companies, Inc. has a twelve month low of $77.05 and a twelve month high of $112.38. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The company has a 50 day moving average of $90.68 and a two-hundred day moving average of $98.56.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. As a group, analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Citigroup dropped their price objective on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. BNP Paribas upgraded shares of Cooper Companies to a “hold” rating in a research note on Thursday, March 13th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. Stifel Nicolaus dropped their price objective on shares of Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Finally, Robert W. Baird lowered their target price on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research note on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $111.89.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.